Jagsonpal Pharmaceuticals Limited Asset Resilience Ratio
Jagsonpal Pharmaceuticals Limited asset resilience ratio. Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has an Asset Resilience Ratio of 30.36% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Jagsonpal Pharmaceuticals Limited (2017–2026)
Asset resilience ratio of Jagsonpal Pharmaceuticals Limited from 2017 to 2026. This chart shows how Jagsonpal Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. Read Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Jagsonpal Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Jagsonpal Pharmaceuticals Limited's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs961.43 Million | 30.36% |
| Total Liquid Assets | Rs961.43 Million | 30.36% |
Asset Resilience Insights
- Very High Liquidity: Jagsonpal Pharmaceuticals Limited maintains exceptional liquid asset reserves at 30.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Jagsonpal Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare Jagsonpal Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Jagsonpal Pharmaceuticals Limited Asset Resilience Ratio by Year (2017–2026)
Jagsonpal Pharmaceuticals Limited asset resilience ratio by year from 2017 to 2026. The table below shows the annual Asset Resilience Ratio data for Jagsonpal Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 30.36% | Rs961.43 Million ≈ $10.40 Million |
Rs3.17 Billion ≈ $34.25 Million |
-11.87pp |
| 2025-03-31 | 42.23% | Rs1.18 Billion ≈ $12.71 Million |
Rs2.78 Billion ≈ $30.09 Million |
-20.04pp |
| 2024-03-31 | 62.27% | Rs1.35 Billion ≈ $14.62 Million |
Rs2.17 Billion ≈ $23.48 Million |
+3.31pp |
| 2023-03-31 | 58.96% | Rs1.15 Billion ≈ $12.43 Million |
Rs1.95 Billion ≈ $21.08 Million |
+30.61pp |
| 2022-03-31 | 28.35% | Rs477.64 Million ≈ $5.17 Million |
Rs1.68 Billion ≈ $18.22 Million |
-10.73pp |
| 2021-03-31 | 39.08% | Rs641.74 Million ≈ $6.94 Million |
Rs1.64 Billion ≈ $17.76 Million |
+9.78pp |
| 2020-03-31 | 29.30% | Rs430.64 Million ≈ $4.66 Million |
Rs1.47 Billion ≈ $15.89 Million |
+6.24pp |
| 2019-03-31 | 23.06% | Rs313.12 Million ≈ $3.39 Million |
Rs1.36 Billion ≈ $14.68 Million |
+16.59pp |
| 2018-03-31 | 6.47% | Rs83.98 Million ≈ $908.23K |
Rs1.30 Billion ≈ $14.04 Million |
-14.95pp |
| 2017-03-31 | 21.42% | Rs305.53 Million ≈ $3.30 Million |
Rs1.43 Billion ≈ $15.42 Million |
-- |
About Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more